AbbVie's Discount vs. Johnson & Johnson's Fortress: Pick One
AbbVie is the cheaper of the two big-cap healthcare names, but its revenue leans on a short list of drugs. Johnson & Johnson sells breadth and balance-sheet strength. Here is how the trade-off looks in 2026.
Motley Fool weighed AbbVie against Johnson & Johnson for 2026, finding AbbVie the cheaper stock but heavily concentrated in a few drugs, while Johnson & Johnson offers a fortress balance sheet and a wider portfolio; ABBV last closed at 255.48 (-1.03%) and JNJ at 268.04 (+0.85%) on Aug. 28, 2026.
Two of the largest healthcare names in the U.S. market ask investors the same question from opposite directions. AbbVie (ABBV) is the cheaper stock, and it is cheaper for a reason: a large share of its revenue sits in a small number of products. Johnson & Johnson (JNJ) costs more per unit of earnings, and what the premium buys is breadth — a wider product portfolio and what Motley Fool describes as a fortress balance sheet.
That is the whole argument, and it is not a new one. What has changed is the price. In the most recent session before this was written, AbbVie last traded at 255.48, down 1.03% from a prior close of 258.15, with a day range of 255.08 to 259.00. Johnson & Johnson closed at 268.04, up 0.85% from 265.77, in a range of 264.27 to 268.38. Both prints are as of the last trade at 20:00 GMT on Aug. 28, 2026; the market is closed.
The two stocks moved in opposite directions on the day
The split is small but it is the shape of the debate in miniature. AbbVie gave up ground while Johnson & Johnson gained, on a session where the broad tape was mildly lower: the S&P 500 tracker closed at $769.35, off 0.23%, the Nasdaq 100 proxy at $716.43, down 0.65%, and the Dow tracker at $535.06, essentially flat at -0.03%.
So Johnson & Johnson outperformed a soft market and AbbVie underperformed it. On headline price alone, Johnson & Johnson's last close sits roughly 4.9% above AbbVie's — an illustrative comparison of the two share prices, not a valuation measure, since share price says nothing about how many shares each company has outstanding.
That distinction matters here more than usual. The lead fact is that AbbVie is the cheaper stock on valuation, not on sticker price. Cheaper valuation means the market is paying less for each dollar of AbbVie's earnings or cash flow than it is for Johnson & Johnson's. The higher nominal share price on JNJ is coincidence.
What concentration risk actually costs a drugmaker
Revenue concentration is the single most consequential structural difference between these two businesses, and it is why the discount exists rather than being a free lunch.
When a large slice of a pharmaceutical company's top line comes from a handful of products, three things follow. First, patent expiry becomes an event rather than a process — the loss of exclusivity on one drug can remove a visible chunk of sales in a compressed window, because biosimilar and generic competitors enter on a known date. Second, the company's growth rests on whether its newer products ramp fast enough to fill the hole left behind, which turns the investment case into a timing question. Third, a single clinical, regulatory or reimbursement setback in one of those franchises hits the whole company, not a division of it.
Investors price that fragility. A stock with heavy concentration typically trades at a lower multiple than an equally profitable diversified peer, and the gap is not mispricing — it is compensation for a narrower base. The judgment an AbbVie buyer is making is that the discount is larger than the risk warrants, and that the successor products are ramping faster than the market credits.
Why a fortress balance sheet is worth paying for in 2026
The phrase gets used loosely, so it is worth being precise about what balance-sheet strength does for a healthcare holder. Low leverage and high credit quality give a company three practical options that a stretched competitor does not have: it can keep funding research through a bad year without cutting the pipeline, it can buy assets when they are cheap rather than when it is forced to, and it can absorb litigation and settlement costs without touching the dividend.
The phrase gets used loosely, so it is worth being precise about what balance-sheet strength does for a healthcare holder.
For a diversified healthcare group, that last point is not theoretical. Legal exposure is a recurring feature of the sector, and a balance sheet that can pay a large one-off cost out of capacity rather than out of shareholder returns is a genuine defensive asset.
Wider portfolio breadth compounds the same effect. A company selling across multiple therapeutic areas, and in some cases across pharmaceuticals and medical devices, has more places for growth to come from and more ways to offset a single disappointment. It also, almost by definition, grows more slowly than a concentrated business whose lead product is compounding.
The framework for choosing, and what to watch next
This is not a case where one stock is good and the other is bad. It is a straight trade between price and durability:
- AbbVie suits an investor who wants the valuation discount and is willing to underwrite the concentration — meaning they are prepared to track individual product performance quarter by quarter and accept that a single franchise can move the whole thesis.
- Johnson & Johnson suits an investor who is buying healthcare as the defensive sleeve of a portfolio and wants the strongest balance sheet and the widest revenue base, accepting that they are paying a premium for both.
- Owning both is a coherent answer for anyone whose real objective is healthcare exposure rather than a winner-picking exercise, since the two carry different risks rather than the same risk twice.
The things that would settle the argument over the next few quarters are specific and observable. On AbbVie: the revenue trajectory of its growth products versus its legacy franchise, and whether management's guidance still implies the gap gets filled on schedule. On Johnson & Johnson: whether portfolio breadth is translating into actual growth rather than merely into stability, and how much balance-sheet capacity is being consumed by legal and settlement costs.
On the tape, both stocks are trading within a couple of percent of their prior closes, and neither day's move tells you anything about which thesis is winning. The valuation gap is the live variable — the wider it gets, the more the market is paying AbbVie holders to carry the concentration, and the more the defensive case for Johnson & Johnson has to justify itself on results rather than on reputation.
Key facts
- ABBV last close: 255.48, -1.03% (Aug. 28, 2026, 20:00 GMT)
- JNJ last close: 268.04, +0.85% (Aug. 28, 2026, 20:00 GMT)
- AbbVie's drawback: Heavy revenue concentration in a small number of products
- Johnson & Johnson's edge: Fortress balance sheet and a wider product portfolio
Frequently asked questions
Which stock is cheaper, AbbVie or Johnson & Johnson?
AbbVie trades at the cheaper valuation of the two, meaning the market pays less for each dollar of its earnings. Note that its nominal share price is also lower — AbbVie last closed at 255.48 versus 268.04 for Johnson & Johnson on Aug. 28, 2026 — but share price alone is not a valuation measure, since it ignores share count.
What does revenue concentration mean for AbbVie shareholders?
It means a large share of sales comes from a small number of drugs. Patent expiry then becomes a dated event rather than a gradual process, and a single clinical, regulatory or pricing setback can hit the entire company rather than one division. That fragility is the main reason the stock carries a valuation discount to more diversified peers.
Why is a 'fortress balance sheet' valuable in healthcare?
Low leverage and strong credit let a drugmaker keep funding research through a weak year, acquire assets opportunistically rather than under pressure, and absorb litigation or settlement costs without cutting the dividend. In a sector with recurring legal exposure, that capacity is a genuine defensive asset for shareholders rather than an accounting nicety.
How did the two stocks perform in the latest session?
They split. AbbVie fell 1.03% to 255.48, trading between 255.08 and 259.00. Johnson & Johnson rose 0.85% to 268.04, in a range of 264.27 to 268.38. The broad market was slightly lower: the S&P 500 tracker closed at $769.35, down 0.23%, and the Nasdaq 100 proxy at $716.43, down 0.65%.
Does the premium on Johnson & Johnson make sense?
It reflects two things investors are willing to pay for: a wider revenue base across multiple therapeutic areas and a stronger balance sheet. The trade-off is that a broader business generally grows more slowly than a concentrated one whose lead products are compounding. Whether the premium is justified depends on results rather than reputation.
Is it reasonable to own both names?
Yes, if the goal is healthcare sector exposure rather than picking a winner. The two carry different risks — product concentration at AbbVie, slower growth from breadth at Johnson & Johnson — rather than the same risk twice, so holding both diversifies the exposure instead of doubling a single bet.
Sources
Photo: World Sikh Organization of Canada · Pexels Licence — source
